Mavacamten
Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.[2]
Clinical data | |
---|---|
Trade names | Camzyos |
Other names | MYK-461 |
License data |
|
Routes of administration | By mouth |
Drug class | Cardiac myosin inhibitor |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C15H19N3O2 |
Molar mass | 273.336 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Mavacamten is a cardiac myosin inhibitor.[2] It was developed by the MyoKardia, a subsidiary of Bristol Myers Squibb.[3]
Mavacamten was approved for medical use in the United States in April 2022.[2][4]
Medical uses
Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.[2]
History
Mavacamten was granted orphan drug designation by the U.S. Food and Drug Administration (FDA).[5]
Society and culture
Names
Mavacamten is the international nonproprietary name (INN).[6]
References
- https://www.tga.gov.au/resources/prescription-medicines-registrations/camzyos-bristol-myers-squibb-australia-pty-ltd
- "Camzyos- mavacamten capsule, gelatin coated". DailyMed. 28 April 2022. Archived from the original on 3 July 2022. Retrieved 15 May 2022.
- "Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise". Business Wire. 17 November 2020. Archived from the original on 29 April 2022. Retrieved 29 April 2022.
- "U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms" (Press release). Bristol Myers Squibb. 28 April 2022. Archived from the original on 29 April 2022. Retrieved 29 April 2022 – via Business Wire.
- "Mavacamten Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 27 April 2016. Archived from the original on 3 July 2022. Retrieved 29 April 2022.
- World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
Further reading
- Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP (2022). "Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial". Journal of Medical Economics. 25 (1): 51–58. doi:10.1080/13696998.2021.2011301. PMID 34907813.
External links
- "Mavacamten". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03470545 for "Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.